BF Biosciences Limited (PSX:BFBIO)

Market Cap	13.44B
Revenue (ttm)	6.88B
Net Income (ttm)	491.40M
Shares Out	88.33M
EPS (ttm)	5.64
PE Ratio	27.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	146,510
Average Volume	222,413
Open	153.10
Previous Close	152.92
Day's Range	151.76 - 154.00
52-Week Range	117.00 - 253.97
Beta	n/a
RSI	47.17
Earnings Date	Feb 27, 2026

About BF Biosciences

BF Biosciences Limited, a biotech pharmaceutical company, manufactures, imports, and sells pharmaceutical products in Pakistan, Nepal, Afghanistan, Mauritania, Switzerland, and internationally. The company offers pharmaceutical products for various therapeutic areas, including cardiometabolic disorders, cardiology, diabetes, anti-obesity, hepatology, gastroenterology, chronic kidney diseases, dermatology, antifungal treatments, antibiotics, antivirals, rheumatoid arthritis, nephrology, and oncology. It also provides injectables in vials, ampoul...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 535
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: BFBIO

Financial Performance

In 2025, BF Biosciences's revenue was 5.84 billion, an increase of 59.55% compared to the previous year's 3.66 billion. Earnings were 447.15 million, an increase of 16.02%.